Tradestie Institutional Equity Comparison Engine

FMKT vs INKT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

INKT Overall Edge

INKT Captures Institutional Edge (1โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MiNK Therapeutics, Inc. Common Stock (INKT) driven by superior Growth & Margin while FMKT counters with relative strength in Momentum & Technical. Fundamentally, FMKT trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus INKT at N/M Forward P/E and -5720.7% operating margin (+0.0% YoY). In options structure, FMKT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against INKT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
FMKT N/M vs INKT N/M Fwd P/E
Growth & Margin Winner INKT
Op Margin N/A vs -5720.7% ยท YoY N/A vs +0.0%
Momentum & Technical Winner FMKT
1Y -9.4% vs -27.2% ยท 52W Pos 10% vs 3%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
FMKT NYSE Arca
The Free Markets ETF
Institutional Equity
$19.88
-1.4% 1D
Market Cap N/A
1M Return -6.92%
1Y Return -9.44%
Forward P/E N/M
Unified AI Score
44.7 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 50.0 Mom 64.0
INKT NASDAQ
MiNK Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$8.02
-6.85% 1D
Market Cap $44.2M
1M Return -20.28%
1Y Return -27.22%
Forward P/E N/M
Unified AI Score
42.8 / 100 HOLD
Tech 33.0 Fund 45.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FMKT -9.44% INKT -27.22% Spread: +17.78 pp (FMKT Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
FMKT TTM Op. Margin: N/A INKT TTM Op. Margin: -5720.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FMKT vs INKT. Trailing 12-month operating profitability (FMKT N/A vs INKT -5720.7%) and valuation multiples (FMKT N/M vs INKT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FMKT (3) vs INKT (5)
Institutional Metric FMKT INKT Criterion Row Winner
Market Capitalization Scale N/A $44.2M Larger Scale INKT
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth INKT
Operating Margin (TTM) Profitability N/A -5720.7% Higher Margin INKT
Net Profit Margin Profitability N/A 0.0% Higher Margin INKT
Return on Equity (ROE) Capital Efficiency N/A -1239.0% Higher ROE INKT
52-Week Range Position Momentum 10% ($20โ€“$23) 3% ($8โ€“$17) Stronger Trend FMKT
Beta / 30D Volatility Risk Regime 0.91ฮฒ ยท 16% Vol 0.59ฮฒ ยท 55% Vol Lower Realized Risk FMKT
Unified Institutional Score Composite Signal 44.7 / 100 (HOLD) 42.8 / 100 (HOLD) Higher Composite FMKT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FMKT vs INKT Buy Guide
FMKT UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live FMKT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
INKT UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live INKT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FMKT nor INKT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.